Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dysport (abobotulinumtoxinA) and Botox (onabotulinumtoxinA) are both injectable neuromuscular blockers derived from botulinum toxin type A. They work by blocking nerve signals to muscles, causing temporary muscle relaxation. Both products are used for cosmetic purposes to reduce facial wrinkles and for therapeutic purposes to treat various medical conditions including cervical dystonia, muscle spasticity, and other disorders characterized by abnormal muscle contractions. While they contain the same active ingredient (botulinum toxin type A), they are manufactured differently with different potencies and potentially different durations of effect. The potency units between these products are not interchangeable, with a typical conversion ratio of 2.5:1 (Dysport:Botox).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on abobotulinumtoxinA + onabotulinumtoxinA.